UroGen Pharma Ltd. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; the supplied filing text does not provide standalone fourth-quarter results. UroGen is an Israeli biotechnology company focused on urothelial and specialty cancers. Its sole approved product is Jelmyto; its lead investigational candidate is UGN-102.
Key financial results
Amounts are in U.S. dollars; millions unless stated otherwise.
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue, all from Jelmyto | $82.7 | $64.4 | +$18.4, about 28.5% |
| Cost of revenue | $9.4 | $7.7 | +$1.7 |
| Gross profit / gross margin | $73.4 / 88.7% | $56.7 / 88.1% | Margin +0.6 percentage points |
| Research and development | $45.6 | $52.9 | −$7.3 |
| Selling and marketing | $54.7 | $51.9 | +$2.8 |
| General and administrative | $38.6 | $30.9 | +$7.7 |
| Operating loss | $(65.5) | $(79.0) | Loss narrowed $13.5 |
| Net loss | $(102.2) | $(109.8) | Loss narrowed $7.5 |
| Net loss per share | $(3.55) | $(4.81) | Improved $1.26 |
| Cash used in operations | $76.4 | $87.6 | Outflow reduced $11.2 |
- Liquidity: At year-end, cash and cash equivalents were $95.0 million and marketable securities were $46.5 million, totaling $141.5 million. Current assets were $169.2 million versus current liabilities of $31.2 million.
- Debt and other obligations: Long-term debt carrying value was $98.6 million. The RTW prepaid forward obligation was $109.7 million; payments to RTW are tied to product sales and may absorb a significant portion of future cash flows. Future minimum operating lease payments were $1.8 million.
- Funding and runway: The company raised $120.0 million gross in a July–August 2023 private placement. Management estimated existing resources and projected revenues would fund planned operations only until the first quarter of 2025 without additional financing; the company and auditor disclosed substantial doubt about the company’s ability to continue as a going concern.
Material changes and business developments
- Jelmyto revenue grew with higher sales volume. Net revenue also reflected higher reserves for 340B chargebacks and estimated Medicare discarded-drug refunds, partly offset by $4.4 million of CREATES Act sales, including $2.4 million in the fourth quarter.
- R&D spending declined mainly as ATLAS activity concluded, ENVISION costs were lower, and fixed MD Anderson collaboration funding ended. Higher UGN-301 study, UGN-102 scale-up, and clinical compensation costs partly offset the decrease.
- Selling and marketing and G&A expenses increased, reflecting commercial promotion and operations, compensation, advisory, recruiting, media, and managed-service costs.
- Interest expense on debt rose to $14.7 million from $8.4 million, primarily because the loans were outstanding for more of 2023 and interest rates increased. Financing expense on the RTW obligation remained approximately $21.6 million.
- The 2023 private placement increased issued and outstanding shares to 32.5 million at year-end from 23.1 million a year earlier; subsequent ATM sales further increased the share count.
Outlook, risks, and unusual items
- UGN-102: The company reported that Phase 3 ENVISION met its primary endpoint, with a 79.2% complete-response rate at three months. In ATLAS, UGN-102 met the primary disease-free-survival endpoint, reducing risk of recurrence, progression, or death by 55%; three-month complete-response rates were 64.8% for UGN-102 alone and 63.6% for TURBT alone. These are reported topline results; ENVISION’s duration-of-response data were expected in 2024. The FDA agreed that the development plan, including 12-month response-duration evaluation, could support an NDA and allowed rolling submission. UroGen expected to complete the rolling NDA submission in September 2024; FDA review and approval are not assured.
- Pipeline: UroGen planned Phase 3 studies of UGN-103 for low-grade intermediate-risk bladder cancer and UGN-104 for low-grade upper-tract cancer in 2024. UGN-301 remained in an enrolling Phase 1 study, with safety and tolerability data expected in mid-2024. These are forward-looking plans disclosed in the filing.
- Debt amendment after year-end: On March 13, 2024, UroGen amended its Pharmakon loan agreement. It must draw an additional $25 million by September 30, 2024, subject to customary conditions. A further $75 million is optional and conditional, including FDA approval of UGN-102 by June 30, 2025. The amended rate is three-month SOFR plus 7.25% plus 0.26161%; principal repayment is scheduled to begin in the second quarter of 2026, subject to a possible one-year extension upon UGN-102 approval.
- Jelmyto patent challenge: Teva notified UroGen on February 25, 2024 that it had filed an ANDA for a generic Jelmyto and challenged two Orange Book patents expiring in January 2031. Orphan Drug exclusivity runs through April 15, 2027. The outcome and timing of any litigation or generic entry remain uncertain.
- Operating risks: The business remains loss-making and dependent on Jelmyto commercialization, future financing, and successful development and approval of UGN-102. Other significant risks include reimbursement changes, reliance on single-source suppliers and contract manufacturers, clinical and regulatory uncertainty, debt and RTW restrictions, and disruption from the Israel conflict. The company reported over 12 months of mitomycin API and/or Jelmyto finished product on hand for planned operations, while noting that prolonged supply interruption could still be harmful.
- Other unusual items: Medicare granted Jelmyto a New Technology APC effective October 1, 2023; future reclassification could affect outpatient access or reimbursement. The filing also reports no material legal proceeding pending, and audited statements received an unmodified opinion, alongside the going-concern warning.
Most important facts for investors to verify
- Whether UroGen secures sufficient financing to address the disclosed runway through Q1 2025, and whether the mandatory Pharmakon tranche is drawn on time and on acceptable terms.
- Final ENVISION 12-month durability results, the completeness and regulatory acceptability of UGN-102’s rolling NDA, and the actual filing and FDA review timetable.
- Jelmyto sales growth, gross margin, reserves and reimbursement trends, including the effects of 340B, discarded-drug refunds, and the New Technology APC status.
- The status and potential consequences of Teva’s ANDA and patent challenge, including any infringement action and applicable review stays.
- Cash burn, debt interest and repayment obligations, RTW’s sales-linked payments, share dilution, and reliance on single-source suppliers.